Literature DB >> 1263405

[Somatostatin -- a review (author's transl)].

C Lucke, H J Mitzkat, A von zur Mühlen.   

Abstract

Somatostatin, a peptide isolated from ovine hypothalami, prevents growth hormone secretion in vivo and in vitro. Moreover, somatostatin interferes with the secretion of various other hormones: TSH insulin, glucagon, gastrin, VIP and GIP. Under certain conditions a blunting effect on the secretion of prolactin and ACTH can be demonstrated.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 1263405     DOI： 10.1007/BF01471574

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


  68 in total

1.  Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels.

Authors:  S S Yen; T M Siler; G W DeVane
Journal:  N Engl J Med       Date:  1974-04-25       Impact factor: 91.245

2.  Total synthesis of hypothalamic "somatostatin".

Authors:  D Sarantakis; W A McKinley
Journal:  Biochem Biophys Res Commun       Date:  1973-09-05       Impact factor: 3.575

3.  Inhibition of adenosine 3',5'-monophosphate accumulation in anterior pituitary gland in vitro by growth hormone-release inhibiting hormone.

Authors:  P Borgeat; F Labrie; J Drouin; A Bélanger; H Immer; K Sestanj; V Nelson; M Götz; A V Schally; D H Coy; E J Coy
Journal:  Biochem Biophys Res Commun       Date:  1974-02-27       Impact factor: 3.575

4.  Inhibition of pancreatic glucagon responses to arginine by somatostatin in normal man and in insulin-dependent diabetics.

Authors:  J E Gerich; M Lorenzi; V Schneider; C W Kwan; J H Karam; R Guillemin; P H Forsham
Journal:  Diabetes       Date:  1974-11       Impact factor: 9.461

5.  Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients.

Authors:  C H Mortimer; W M Tunbridge; D Carr; L Yeomans; T Lind; D H Coy; S R Bloom; A Kastin; C N Mallinson; G M Besser; A V Schally; R Hall
Journal:  Lancet       Date:  1974-04-20       Impact factor: 79.321

6.  Inhibition of insulin secretion by somatostatin.

Authors:  K G Alberti; N J Christensen; S E Christensen; A P Hansen; J Iversen; K Lundbaek; K Seyer-Hansen; H Orskov
Journal:  Lancet       Date:  1973-12-08       Impact factor: 79.321

7.  Growth-hormone release-inhibiting hormone in gastrointestinal and pancreatic D cells.

Authors:  J M Polak; A G Pearse; L Grimelius; S R Bloom
Journal:  Lancet       Date:  1975-05-31       Impact factor: 79.321

8.  Direct inhibition of gastric acid by growth-hormone release-inhibiting hormone in dogs.

Authors:  A A Barros D'Sa; S R Bloom; J H Baron
Journal:  Lancet       Date:  1975-04-19       Impact factor: 79.321

9.  [Inhibition by somatostatin of pancreatic juice and enzyme secretion and gallbladder contraction in man induced by secretin and cholecystokinin-pancreozymin administration (author's transl)].

Authors:  W Creutzfeldt; P G Lankisch; U R Fölsch
Journal:  Dtsch Med Wochenschr       Date:  1975-05-16       Impact factor: 0.628

10.  Bromocriptine treatment of acromegaly.

Authors:  M O Thorner; A Chait; M Aitken; G Benker; S R Bloom; C H Mortimer; P Sanders; A S Mason; G M Besser
Journal:  Br Med J       Date:  1975-02-08
View more
  2 in total

1.  Clinical evaluation of somatostatin as a potential ajunct to insulin in the management of diabetes mellitus.

Authors:  J E Gerich; T A Schultz; S B Lewis; J H Karam
Journal:  Diabetologia       Date:  1977-09       Impact factor: 10.122

2.  Inhibition by somatostatin of adenosine-3',5'-monophosphate stimulated hepatic ribosomal protein synthesis.

Authors:  K H Tragl; H Kinast
Journal:  Klin Wochenschr       Date:  1977-07-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.